Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.
Essure “permanent” birth control has an unacceptably high rate of placement failure, even when done by those with experience. Yet, the product was approved and this information was buried. Improper placement can result in organ perforation, among other things, and require surgery to remove the device.
The FDA granted fast track approval to Boeheringer’s latest drug offering, Praxbind. This new drug is the long-awaited antidote to new gen anticoagulant, Pradaxa. Preliminary clinical trials suggest an 89% efficacy rate within four hours of IV administration. This could be a life-saving tool for medical providers caring for patients on Pradaxa, a drug known for its high risk of uncontrollable and even fatal belleding events.
The failure rate of “permanent” birth control implant, Essure, is several times that which is advertised by Bayer, its maker. In fact, it is several times that of tubal ligation, the surgical procedure Essure was meant to replace.
Despite hundreds of lawsuits and mind-bogglingly huge settlements, Big Pharma doesn’t seem inclined to clean up its act and produce drugs that are actually safe. None of the current activities seem to matter to the industry. Here’s a look at why suing Big Pharma isn’t changing anything.
Dr. Julio Novoa, OG/GYN, takes a moment to detail Bayer’s untrustworthy “profits over patients” history as well as provide data on the Essure implantable “permanent” birth control device. The video explains the massive campaign of untruth maintained by Bayer regarding the safety and efficacy of the Essure product.
Brandi Casey, a former model and Essure victim, bravely speaks out about her experience with this dangerous medical device. She suffers from metal toxicity and a host of other adverse effects caused by Essure. Yet it’s maker, Bayer, and the FDA continue to tout it as a safe product.
An independent watchdog group, the Project on Government Oversight (POGO), found that the FDA’s approval of anti-coagulant drug Pradaxa was flawed. The POGO report details many poor decisions and conflicts of interest on the FDA’s part as it gave Boehringer, Pradaxa’s maker, several accommodations.
Researchers discovered that there may be a link between favoring bitter tastes, such as black coffee, and less-than-positive personality traits. In fact, the study showed that those who prefer black coffee are more likely to be vain, manipulative, selfish, sadistic and even psychopathic.
Bayer may have tampered with data from clinical trials and patient surveys pertaining to adverse effects caused by its Essure “permanent” birth control product. Patient surveys were altered, eliminating some valuable patient feedback. An advisory panel to the FDA met in late September to discuss Essure’s safety.
New York’s AG is investigating Martin Shkreli of Turing Pharmaceuticals for possible violation of antitrust laws. It seems Big Pharma’s bad boy has set up a distribution network for the anti-parasitic drug, Daraprim, that will all but eliminate the possibility of generic competition. Needless to say, AG Eric Schneiderman is not pleased.